This is a working overview of GHS-R1a, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-04-06. Anything still debated is marked as such rather than presented as settled.
Ipamorelin is a synthetic pentapeptide that belongs to the growth hormone secretagogue family. Its sequence is Aib-His-D-2-Nal-D-Phe-Lys-NH2, incorporating two non-natural residues that resist enzymatic breakdown. Researchers at Novo Nordisk described the compound in the 1990s while searching for agents that release growth hormone with fewer side effects than earlier secretagogues. The molecule acts as an agonist at the ghrelin receptor, also called GHS-R1a, which is expressed in the pituitary and in several peripheral tissues.
Selectivity distinguishes ipamorelin from first-generation secretagogues such as GHRP-6. At doses that reliably raise growth hormone, it shows little stimulation of adrenocorticotropic hormone or cortisol release in animal models, and it does not markedly raise prolactin or appetite. Binding at GHS-R1a on pituitary somatotrophs triggers calcium influx and pulsatile growth hormone secretion. Because the compound mimics the natural ghrelin signal, the release pattern tends to follow the body's own rhythm rather than producing a sustained elevation.
Ipamorelin 是一种合成五肽，序列为 Aib-His-D-2-Nal-D-Phe-Lys-NH2，分子式 C38H49N9O5，游离碱分子量约 711.85 g/mol。它属于生长激素促分泌素（GHS）家族，作用靶点是胃饥饿素受体 GHS-R1a。该化合物由诺和诺德的研究团队在二十世纪九十年代末报道，设计目标是提高对生长激素释放的选择性。C 端酰胺化与 N 端 Aib 残基是两个用于抵抗肽酶降解的结构特征。
在 GHS 家族中，早期肽类如 GHRP-6 与 GHRP-2 会同时促进生长激素、皮质醇与催乳素的释放，并明显增加食欲。Ipamorelin 在动物与早期人体研究中表现出对生长激素释放的相对选择性，对上述其他激素的影响较小。这种差异通常归因于受体结合模式与下游信号偏向的不同，而完整的分子解释仍有待补充。需要区分的是，选择性是研究观察中的相对程度，并非绝对界限。
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C38H49N9O5 | Includes two non-natural residues |
| Molecular weight | About 711.9 g/mol | Confirmed by mass spectrometry |
| Appearance | White to off-white powder | Typical lyophilized form |
| Receptor target | GHS-R1a | Ghrelin receptor agonist |
| Plasma half-life | Roughly 2 hours | Varies by species and assay |
Ipamorelin is a synthetic pentapeptide that acts on the growth hormone secretagogue receptor, also known as the ghrelin receptor. Its sequence contains five amino acid residues, including a non-natural residue that increases stability against enzymatic breakdown. The compound was developed in the 1990s as part of research into small peptides that stimulate pituitary hormone release. Unlike larger protein hormones, it can be produced by solid-phase peptide synthesis and characterized by standard analytical methods.
At the receptor level, ipamorelin binds GHS-R1a and triggers signaling through Gq-coupled pathways. Activation leads to calcium release and downstream effects in pituitary somatotroph cells. These events promote the release of growth hormone into circulation. The response depends on the presence of the receptor and on the physiological state of the animal or tissue studied. Because the receptor is also found in other tissues, effects beyond the pituitary have been examined in laboratory models, though the extent of those effects remains an area of ongoing study.
The compound was developed at Novo Nordisk during the 1990s as part of a programme seeking secretagogues with improved selectivity. It was described in the peer-reviewed literature in 1998 alongside related pentapeptides from the same series. Investigators advanced it because it raised growth hormone output in animal models while leaving other pituitary hormones comparatively unaffected. The development code NNC 26-0161 appears in earlier reports, and ipamorelin later became the common designation in published work.
Selectivity is the property most often attached to this peptide. Published animal and early human studies record increases in growth hormone release after administration, with adrenocorticotropic hormone and cortisol responses remaining small by comparison. Effects on appetite-related pathways also appear weaker than those reported for several earlier secretagogues. Reviews that compare members of the growth hormone secretagogue family cite these findings frequently, though the receptor-level explanation for the selectivity continues to be debated rather than settled.
=== Pharmacokinetics === Chloral hydrate is metabolized to both 2,2,2-trichloroethanol (TCE) and trichloroacetic acid (TCA) by alcohol dehydrogenase. TCE is further converted to its glucoronide. Dichloroacetic acid (DCA) has been detected as a metabolite in children, but how it gets made is unknown. TCE glucoronide, TCA, and a very small amount of free TCE are excreted in urine in male human adults. This study did not detect significant amounts of DCA; the authors noted that DCA can form during inappropriate sample preparation. Both TCA and DCA cause liver tumors in mice. TCA is cleared by the kidneys at a rate slower than the expected filtration rate, suggesting that efficient reabsorption of filtered-out TCA happens.
=== Naming === In Mendeleev's nomenclature for unnamed and undiscovered elements, meitnerium would be called eka-iridium. In 1979, during the Transfermium Wars (but before the synthesis of meitnerium), IUPAC published recommendations per which the element was to be called unnilennium (symbol Une), a systematic element name as a placeholder, until the element is discovered (and the discovery then confirmed) and a permanent name is decided on. Though widely used in the chemical community on all levels, from chemistry classrooms to advanced textbooks, the recommendations were mostly ignored among scientists in the field, who either called it "element 109", with the symbol E109, (109) or even simply 109, or used the proposed name "meitnerium". The naming of meitnerium was discussed in the Transfermium Wars regarding the names of elements 104–109, but meitnerium was the only proposal and thus was never disputed. The name meitnerium (Mt) was suggested by the GSI team in September 1992 in honor of Austrian physicist Lise Meitner, a co-discoverer of protactinium (with Otto Hahn), and one of the discoverers of nuclear fission. In 1994 the name was recommended by IUPAC, and was officially adopted in 1997. It is thus the only element named solely after a non-mythical woman (curium is named for both Pierre and Marie Curie).
== Distribution == UCN III is widely distributed throughout the brain and is present in many bodily tissues—including the skin, gastrointestinal tract (GI tract), pancreatic beta cells, kidneys, heart, endocrine system, and brain. The medial amygdala (MeA), rostral perifornical area of the hypothalamus, bed nucleus of the stria terminalis (BNST), superior paraolivary nucleus, nucleus parabrachialis, and premammillary nucleus are the primary locations where UCN III is expressed. Expression of UCN III occurs late in the differentiation process of beta cells, where it is necessary for complete insulin secretion triggered by glucose and incretin, and is shown in mature beta cells in both mice and humans. Beta cells use the ATP-sensitive potassium channel (KATP channel) to facilitate the glucose-dependent release of UCN III. This is corroborated by the expression of PC1/3, Nkx6.1, and Pdx1 in hESC-derived UCN III + beta cells. But human UCN III is not specific to the beta cell lineage; rather, it is a generic marker for both the alpha and beta cell lineages, as seen by its expression in primary and hESC-derived alpha cells. A universal marker of alpha and beta cell development in humans is Ucn III. After triggering the receptors in the cerebral endothelial cells, UCN III crosses the blood–brain barrier, as demonstrated by a transneuronal tracer injection into the ventral pre-mammillary nucleus of the rat brain.
Sources: en.wikipedia.org
Instead of in the liquid phase, the dehydrochlorination may also be carried out in the gas phase on a zinc chloride impregnated catalyst in a fluidized bed reactor at 350-500 °C. The seemingly simple reaction yields only 70 to 80% of impure end product due to a variety of side reactions. For example, in the chlorination of ethylene carbonate in substance or solution, 2-chloroacetaldehyde, polychlorinated ethylene carbonate and chlorinated ring-opening products are formed besides others. The separation of the by-products from the final product by distillation by thin-film evaporator, fractional recrystallization or zone melting is very expensive. The content of by-products can be reduced by stirring with sodium borohydride or urea at elevated temperature. However, the purification is complicated by the pronounced thermolability of vinylene carbonate, as it decomposes at temperatures above 80 °C within minutes. Highly pure vinylene carbonate can be obtained in yields of more than 70% by optimizing the chlorination conditions to suppress the formation of by-products and a combination of several gentle purification processes. The tendency of the liquid vinylene carbonate to polymerize is suppressed by addition of inhibitors such as butylhydroxytoluene (BHT).
=== Pundits === Frank Chodorov (1907), conservative activist, founder of the Intercollegiate Studies Institute, editor of The Freeman Arnold Beichman (1934), conservative critic Ralph de Toledano (1938), conservative commentator, editor of National Review and Newsweek Joseph Kraft (1947), political columnist, speechwriter for John F. Kennedy Jules Witcover (1949), columnist, The Baltimore Sun Norman Podhoretz (1950), a "father of neoconservatism", editor of Commentary Magazine and author of Making It Jeffrey Hart (1952), conservative cultural critic and advisor to the Dartmouth Review David Horowitz (1959), conservative commentator and activist; author of the Academic Bill of Rights Herbert London (1960), conservative activist; former professor at New York University and first dean of the Gallatin School of Individualized Study; former president of conservative think tank Hudson Institute D. Keith Mano (1963), conservative political commentator for National Review Lawrence Auster (1971), Traditionalist conservative blogger and essayist Andrew Levy (1988), conservative commentator and host of Red Eye on Fox News
Public health laboratories (PHLs) or National Public Health Laboratories (NPHL) are governmental reference laboratories that protect the public against diseases and other health hazards. The 2005 International Health Regulations came into force in June 2007, with 196 binding countries that recognised that certain public health incidents, extending beyond disease, ought to be designated as a Public Health Emergency of International Concern (PHEIC), as they pose a significant global threat. The PHLs serve as national hazard detection centres, and forward these concerns to the World Health Organization.
Sources: en.wikipedia.org
The peptide is Aib-His-D-2-Nal-D-Phe-Lys-NH2. Two of its residues are non-natural, which slows enzymatic degradation. The C-terminal amide is common among bioactive peptides.
It binds the same ghrelin receptor but with greater selectivity in functional assays. Preclinical work reports less cortisol and prolactin stimulation at growth-hormone-releasing doses. Those differences are relative, not absolute, and depend on dose and model.
No major regulatory authority has approved it for human therapeutic use. It is sold as a research chemical for laboratory investigation. Clinical status varies by country and is subject to change.
两者都是 GHS-R1a 激动剂，但 ipamorelin 在研究中显示出更高的生长激素释放选择性。早期资料显示它对皮质醇、催乳素与食欲的刺激弱于 GHRP-6。这些差异是相对程度，而非绝对区分。